La cadena de opciones muestra datos clave de las opciones de acciones de Aclaris Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Aclaris Therapeutics..

Aclaris Therapeutics (NASDAQ:ACRS) Bolsa, Cadena de Opciones

Aclaris Therapeutics

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics Inc

Scotiabank analyst Louise Chen initiates coverage on Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) with a Sector Outperform rating and announces Price Target of $15.

News

Price Target

Initiation

Analyst Ratings

ACRS

Scotiabank Initiates Coverage On Aclaris Therapeutics with Sector Outperform Rating, Announces Price Target of $15

Guidance

Aclaris Therapeutics Expects Cash Runway Into 2028

Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0.24) by 320.83 percent. The company reported quarterly sales of $9.21 million which beat the analyst consensus estimate of $2.11 million by 336.89 percent. This is a 47.58 percent decrease over sales of $17.57 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Aclaris Therapeutics Q4 2024 GAAP EPS $(1.01) Misses $(0.24) Estimate, Sales $9.21M Beat $2.11M Estimate

Aclaris Therapeutics Announced The Availability Of A New Publication Describing The Unique Properties Of Aclaris Therapeutics' ATI-2138, A Novel Investigational Covalent Inhibitor Of Interleukin-2-inducible T Cell Kinase And Janus Kinase 3 In Development For The Treatment Of Autoimmune And Inflammatory Diseases

HC Wainwright &amp; Co. analyst Raghuram Selvaraju upgraded Aclaris Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Neutral to Buy and a <a href="https://www.benzinga.com/quote/ACRS/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $20</a>. The stock gained after the rerating.
In a press release last month, Aclaris announced that it had entered into an exclusive license agreement with privately held Biosion, Inc. for worldwide rights (excluding Greater China) to BSI-045B, a potential best-in-class, clinical-stage, novel anti-TSLP monoclonal antibody, and BSI-502, a potential best-in-class, preclinical-stage, novel bispecific antibody directed against both TSLP and IL4R.
Despite recent advances in anti-TSLP and anti-IL4R therapies, there remains a substantial unmet need for more effective and convenient treatment options.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/24/12/42631016/taiwan-semiconductor-expands-in-japan-sony-and-denso-among-first-customers" rel="noreferrer noopener">Taiwan Semiconductor Expands in Japan: Sony and Denso Among First Customers</a>
In a completed Phase 2a, single-arm, proof-of-concept trial conducted in the U.S. in 22 patients with moderate-to-severe atopic dermatitis, BSI-045B was observed to have a pharmacodynamic, safety, and efficacy profile that could position it as a potential best-in-class therapy.
BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion&#8217;s regional partner, targeting severe asthma and chronic rhinosinusitis with nasal polyps, accelerating the potential to show proof-of-concept across additional indications.
Selvaraju expects Aclaris to initiate multiple mid-stage clinical studies next year in the U.S. due to potential positive results from the Chinese trials. 
This should pave the way for registration programs in the coming years. From Selvaraju&#8217;s vantage point, BSI-045B could generate billions of dollars in sales across solely the U.S. and European Union markets in only chronic asthma and atopic dermatitis indications.
This candidate could reach the U.S. market in 2029 to treat chronic asthma and in 2030 for treating AD, with potential peak annual sales of roughly $9.8 billion. 
Selvaraju&#8217;s forecasts include pricing in the $30K range in the U.S. and the $10K range in Europe, roughly in line with net pricing for Dupixent (dupilumab), the most commercially successful of the currently-marketed anti-IL-4R monoclonal antibodies with estimated 2024 sales totaling roughly 13 billion euros. 
Selvaraju noted that an earlier-generation monoclonal antibody, the anti-IgE agent Xolair (omalizumab), generated sales approaching $4 billion in 2023. Selvaraju ascribed a 30% probability of approval to BSI-045B in chronic asthma and a 20% probability of approval to this candidate in AD.
Selvaraju projected fourth-quarter revenue of $2.9 million and EPS of $(0.10).
Price Action: ACRS stock is up 8% at $2.94 at last check Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42627181/blackberry-growth-hinge-on-iot-secure-communications-despite-valuation-concerns-analyst" target="_blank" rel="noreferrer noopener">BlackBerry Growth Hinge On IoT, Secure Communications Despite Valuation Concerns: Analyst</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock.com

Upgrades

Trading Ideas

Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Raymond James analyst Buck Horne upgraded the rating for Weyerhaeuser Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>) from Market Perform to Outperform and announced a $32 price target. Weyerhaeuser shares closed at $27.50 on Friday. <a href="https://www.benzinga.com/quote/WY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. analyst Raghuram Selvaraju upgraded the rating for Aclaris Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Neutral to Buy and maintained the price target of $20. Aclaris Therapeutics shares closed at $2.72 on Friday. See how other analysts view this stock.</li>
<li>Piper Sandler analyst Crispin Love upgraded GCM Grosvenor Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCMG#NASDAQ">GCMG</a>) from Neutral to Overweight and raised the price target from $12.5 to $14. GCM Grosvenor shares closed at $11.75 on Friday. <a href="https://www.benzinga.com/quote/GCMG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Buck Horne upgraded the rating for PotlatchDeltic Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCH#NASDAQ">PCH</a>) from Market Perform to Outperform and announced a $45 price target. PotlatchDeltic shares closed at $38.75 on Friday. <a href="https://www.benzinga.com/quote/PCH/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying WY stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="592" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191-1024x592.png" alt="" class="wp-image-704426" style="width:637px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191-1024x592.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191.png 1078w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>

Markets

GCMG

This Weyerhaeuser Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday

HC Wainwright &amp; Co. analyst Raghuram Selvaraju upgrades Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Neutral to Buy and maintains the price target from $20 to $20.

HC Wainwright & Co. Upgrades Aclaris Therapeutics to Buy, Maintains Price Target to $20

<h3>Gainers</h3>
<ul>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) stock moved upwards by 26.4% to $3.26 during Tuesday's pre-market session. The company's market cap stands at $4.3 million. </li>
<li>Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) shares increased by 19.1% to $3.74. The company's market cap stands at $267.1 million. </li>
<li>Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) shares rose 15.74% to $10.0. The market value of their outstanding shares is at $544.0 million. The company's, Q3 earnings came out 4 days ago. </li>
<li>TFF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) shares rose 15.41% to $0.42. The company's market cap stands at $1.4 million. </li>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares increased by 15.32% to $1.43. The company's market cap stands at $54.0 million. As per the press release, Q3 earnings came out 3 days ago. </li>
<li>Fresh2 Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) stock rose 14.36% to $1.1. The company's market cap stands at $26.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) stock fell 16.3% to $0.16 during Tuesday's pre-market session. The market value of their outstanding shares is at $17.8 million. </li>
<li>Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) stock fell 12.31% to $67.5. The market value of their outstanding shares is at $13.0 billion. </li>
<li>Cytek Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) stock declined by 10.78% to $5.38. The market value of their outstanding shares is at $693.0 million. </li>
<li>Grifols (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares fell 10.42% to $8.26. The company's market cap stands at $5.6 billion. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares decreased by 9.8% to $0.26. The company's market cap stands at $1.4 million. As per the press release, Q3 earnings came out 3 days ago. </li>
<li>Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) stock decreased by 9.26% to $25.0. The company's market cap stands at $4.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ALKS

ALMS

APLM

CTKB

FRES

GCTK

GRFS

HCWB

INCY

SNOA

TFFP

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

On Monday, Aclaris Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) entered into an exclusive license agreement with Biosion Inc for worldwide rights (excluding Greater China) to BSI-045B and BSI-502, a preclinical-stage, novel bispecific antibody directed against <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42034751/aclaris-therapeutics-announces-exclusive-global-license-agreement-with-biosion-inc-adding-potentia" rel="noreferrer noopener">both TSLP and IL4R</a>.
In a completed Phase 2a, single-arm, proof-of-concept trial in the United States in 22 patients with moderate to severe atopic dermatitis, BSI-045B was observed to have a pharmacodynamic, safety, and efficacy profile.
BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion&#8217;s regional partner, Chia Tai Tianqing Pharmaceutical Group, Co., Ltd. (CTTQ), targeting severe asthma and chronic rhinosinusitis with nasal polyps, accelerating the potential to show proof-of-concept across additional indications.
Under the terms of the agreement, Biosion shall receive over&nbsp;$40 million&nbsp;cash payment as an upfront license fee and reimbursement for certain development costs &amp; drug product materials.
Biosion shall also receive 19.9% shares of Aclaris Therapeutics.
Additional regulatory and sales milestone payments exceed&nbsp;$900 million, with tiered low-to-mid single-digit royalty payments based on a percentage of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42036056/biosion-announces-exclusive-global-license-agreement-with-aclaris-therapeutics-on-two-potential-fi" rel="noreferrer noopener">annual net sales</a>.
Leerink Partners upgraded Aclaris from Market Perform to Outperform, with a price target of $7, <a target="_blank" href="https://www.benzinga.com/quote/ACRS/analyst-ratings" rel="noreferrer noopener">up from $2</a>.
The analyst writes, &#8220;Following completion of their strategic review, we expect investor focus to shift to ACRS&#8217; newly strengthened immunology-focused pipeline.&#8221;
Leerink writes that these updates mark a fresh start for Aclaris Therapeutics, with a clear strategic direction and promising catalysts in the next 6-12 months. This progress could reduce risks for BSI-045B and significantly enhance its value.
The analyst has updated the model to include BSI-045 B&#8217;s potential in atopic dermatitis (AD), estimating around $1.3 billion in revenue by 2035 with a 35% probability of success. The analyst also anticipates multiple Phase 2 trial results from China in asthma and chronic rhinosinusitis with nasal polyps, which could provide more insight into BSI-045 B&#8217;s potential.
Additionally, Leerink expects further progress in de-risking the company&#8217;s pipeline in the first half of next year.
BTIG upgrades Aclaris Therapeutics from Neutral to Buy and announces a $8 price target.
Price Action: ACRS stock is up 55.60% at $4.88 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42063475/interactive-strength-shares-jumps-premarket-as-saudi-fitness-chain-adopts-clmbr-machines" target="_blank" rel="noreferrer noopener">Interactive Strength Shares Jump As Saudi Fitness Chain Adopts CLMBR Machines: Details</a></li>
</ul>

Analyst Color

Biotech

Health Care

Contracts

General

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/607ebdb217ff280001130e2a/julian-harrison">BTIG analyst Julian Harrison</a> upgraded the rating for Aclaris Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Neutral to Buy and announced a price target of $8. Aclaris Therapeutics shares closed at $3.14 on Monday. <a href="https://www.benzinga.com/quote/ACRS/analyst-ratings">See how other analysts view this stock.</a></li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/650428998345120001a2f3ec/wesley-brooks">HSBC analyst Wesley Brooks</a> upgraded the rating for QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) from Reduce to Hold and announced a price target of $5.3. QuantumScape shares closed at $4.73 on Monday. <a href="https://www.benzinga.com/quote/QS/analyst-ratings">See how other analysts view this stock.</a></li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5809e400846faa000106ad3a/cory-kasimov">Evercore ISI Group analyst Cory Kasimov</a> upgraded the rating for BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) from In-Line to Outperform and boosted the price target from $110 to $125. BioNTech shares closed at $101.87 on Monday. <a href="https://www.benzinga.com/quote/BNTX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity analyst Matthew Lee upgraded Bank of Nova Scotia (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BNS#TSX">BNS</a>) from Hold to Buy and raised the price target from C$71 to C$84. <a href="https://www.benzinga.com/quote/BNS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies analyst Roger Song upgraded the rating for Aclaris Therapeutics, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Hold to Buy and raised the price target from $2 to $7. Aclaris Therapeutics shares closed at $3.14 on Monday. <a href="https://www.benzinga.com/quote/acrs/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying BNTX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="559" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19073934/image-195-1024x559.png" alt="" class="wp-image-654905" style="width:678px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19073934/image-195-1024x559.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19073934/image-195-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19073934/image-195-768x419.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19073934/image-195.png 1205w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42035732/jim-cramer-super-group-basic-materials-stock-is-very-hard-to-own-here">Jim Cramer: Super Group Finally &#8216;Broke Out,&#8217; This Basic Materials Stock Is &#8216;Very Hard To Own Here&#8217;</a></li>
</ul>

Pre-Market Outlook

ACHR

ACNB

BNTX

TSX:BNS

This BioNTech Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Leerink Partners analyst Thomas Smith upgrades Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Market Perform to Outperform and raises the price target from $2 to $7.

Leerink Partners Upgrades Aclaris Therapeutics to Outperform, Raises Price Target to $7

Jefferies analyst Roger Song upgrades Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Hold to Buy and raises the price target from $2 to $7.

Jefferies Upgrades Aclaris Therapeutics to Buy, Raises Price Target to $7

WIIM

Aclaris Therapeutics shares are trading higher after Piper Sandler upgraded the stock from Neutral to Overweight and raised its price target from $3 to $13. Also, BTIG upgraded the stock from Neutral to Buy and announced a price target of $8.

BTIG analyst Julian Harrison upgrades Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Neutral to Buy and announces $8 price target.

BTIG Upgrades Aclaris Therapeutics to Buy, Announces $8 Price Target

Piper Sandler analyst Christopher Raymond upgrades Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Neutral to Overweight and raises the price target from $3 to $13.

Piper Sandler Upgrades Aclaris Therapeutics to Overweight, Raises Price Target to $13

Aclaris Therapeutics Shares Spike Higher; Piper Sandler Upgrades Stock To Overweight With $13 Target Following Biosion Deal; Highlights Pipeline For Atopic Dermatitis And I&I Market, Catalysts Expected In 2025 Trials

Aclaris Therapeutics shares are trading higher after the company announced it entered into an exclusive license agreement with Biosion for worldwide rights to BSI-045B. The company announced an $80 million private placement.

Aclaris Therapeutics Secures $80M Through Private Placement Of 35.56M Shares At $2.25 Per Share; Funds To Support Pipeline Development And General Corporate Purposes

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion For Worldwide Rights (Excluding Greater China) To BSI-045B

Aclaris Had Aggregate Cash, Cash Equivalents And Marketable Securities Of $173.4M As Of September 30, Which Is Expected To Provide Cash Runway Into 2028

Press Releases

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

This Healthcare Stock is Soaring Following Exclusive License Agreement Announcement

Peraso Inc. (NASDAQ: PRSO): Intro-Act Targets $3.30 Per Share After Positive Q3 Performance see more stocks inside….

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

Comments

Aclaris Therapeutics

Aclaris Therapeutics (ACRS) Opciones

Aclaris Therapeutics (NASDAQ:ACRS) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL